<DOC>
	<DOCNO>NCT02974907</DOCNO>
	<brief_summary>The objective study compare safety efficacy RGN-259 Ophthalmic Solutions placebo treatment sign symptom dry eye .</brief_summary>
	<brief_title>Assessment Safety Efficacy RGN-259 Ophthalmic Solutions Dry Eye Syndrome : ARISE-2</brief_title>
	<detailed_description>Dry eye cause many variable factor . Some example include hormonal change due aging , live environment low humidity long periods time . Dry eye complex disease may result symptom like discomfort , visual disturbance , dryness . Patients dry eye often damage surface eye . In previous study , RGN-259 show promote heal surface eye decrease inflammation . It suggest RGN-259 significant potential important new safe effective therapeutic treatment dry eye syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Be least 18 year age ; Provide write informed consent ; Have subject report history dry eye least 6 month Have history use desire use eye drop dry eye symptom within 6 month Have clinically significant slitlamp finding Visit 1 may include active blepharitis , meibomian gland dysfunction ( MGD ) , lid margin inflammation active ocular allergy require therapeutic treatment , and/or opinion investigator may interfere study parameter ; Be diagnose ongoing ocular infection ( bacterial , viral , fungal ) , active ocular inflammation Visit 1 ; Have ab uncontrolled systemic disease :</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Dry Eye Syndrome</keyword>
	<keyword>Dry Eye</keyword>
	<keyword>DES</keyword>
</DOC>